Early trials in the 2000s did not show meaningful weight loss versus placebo, and it never received FDA approval for that use
"Just like if you were on a hypertension medicine or one for diabetes, long-term treatment is necessary," Moore added
Inconsistency during this phase significantly diminishes outcomes
Koeth RA, Wang Z, Levison BS, Buffa JA, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL: Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
For pharma stakeholders, the message is clear: the obesity and diabetes drug market is not just a therapeutic opportunity, but a strategic growth engine for the next decade.